Lexicon Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Lexicon Pharmaceuticals, Inc. (LXRX)

Q1 2012 Earnings Conference Call

May 3, 2012 11:00 ET

Executives

Wade Walke – Senior Director, Communications and Investor Relations

Dr. Arthur Sands – President and Chief Executive Officer

Dr. Pablo Lapuerta – Senior Vice President, Clinical Development and Chief Medical Officer

Jeff Wade – Executive Vice President, Corporate Development and Chief Financial Officer

Analysts

Karen Jay – JPMorgan

Phil Nadeau – Cowen and Company

Alan Carr – Needham & Company

Liana Moussatos – Wedbush Securities

Stephen Willey – Stifel Nicolaus

David Freedman – Morgan Stanley

Presentation

Operator

Welcome to the Lexicon Pharmaceuticals' First Quarter 2012 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at Lexicon’s request.

At this time, I would like to introduce your host for today’s call, Wade Walke, Senior Director of Communications and Investor Relations. Please go ahead, Dr. Walke.

Wade Walke – Senior Director, Communications and Investor Relations

Good morning and welcome to the Lexicon Pharmaceuticals' first quarter 2012 conference call. I am Wade Walke and with me today are Dr. Arthur Sands, Lexicon’s President and Chief Executive Officer; Dr. Brian Zambrowicz, Lexicon’s Executive Vice President and Chief Scientific Officer; Dr. Pablo Lapuerta, Lexicon’s Senior Vice President of Clinical Development and Chief Medical Officer; .and Jeff Wade, Lexicon’s Executive Vice President of Corporate Development and Chief Financial Officer.

We expect that you have seen a copy of our earnings press release that was distributed this morning. During this call, we will review the information provided in the release, provide an update on our clinical programs, and then use the remainder of our time to answer your questions.

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

4 Smaller Biotech Names Worth Researching

7 Things to Watch in Biotech Now

These 3 Biotech Stocks Are Already Moving Wildly on Thursday